Combinatorial effects of telmisartan and docetaxel on cell viability and metastatic gene expression in human prostate and breast cancer cells

Document Type : Original article

Authors

1 Department of Biochemistry, School of Medicine, Shiraz University of Medical Sciences, Shiraz, Iran

2 Student Research Committee, Shiraz University of Medical Sciences, Shiraz, Iran

3 Autophagy Research Center, Shiraz University of Medical Sciences, Shiraz, Iran

4 Molecular Medicine Department, School of Advanced Medical Sciences and Technology, Shiraz University of Medical Sciences, Shiraz, Iran

5 Stem Cell Technology Research Center, Shiraz University of Medical Sciences, Shiraz, Iran

6 Bone and Joint Diseases Research Center, Shiraz University of Medical Sciences, Shiraz, Iran

Abstract

The epithelial-to-mesenchymal transition (EMT) is a unique process resulting in enhanced cell motility, invasiveness, and metastasis in cancer. The EMT is regulated by several transcription factors, including Snail and Slug, which exert crucial roles during cancer progression. We have studied the effects of Docetaxel as the first-line chemotherapy agent for prostate cancer, and Telmisartan as an anti-hypertensive drug on the expression level of Snail and Slug. In addition, the effects of Docetaxel, Telmisartan and their combination on cancer cell proliferation were investigated. The PC3, DU145, MDA-MB468, and HEK cell lines were used for this study. Quantitative RT-PCR analysis and MTT assay were used to study the expression of Snail and Slug level and cell proliferative assay, respectively. We found that a combination of Docetaxel + Telmisartan effectively inhibits the cell proliferation in cancerous cells in comparison with each drug alone (P<0.05). Furthermore, in these cell lines, Docetaxel, Telmisartan and their combination significantly diminished the expression level of Snail and Slug genes compared to control cells (P<0.001), however, in the HEK cell line, this effect was seen only in the combination group. Our data imply that Telmisartan and its combination with Docetaxel exert strong inhibitory effects on the expression level of Snail and Slug genes. Also, these drugs and their combination could inhibit cancer cell proliferation. In conclusion, the combination of Telmisartan and Docetaxel has the potential to suppress the metastasis of prostate and breast cancer cells.

Keywords

References

  1. Lu X, Chen D, Yang F, Xing N. Quercetin inhibits epithelial-to-mesenchymal transition (EMT) process and promotes apoptosis in prostate cancer via downregulating lncRNA MALAT1. Cancer Manag Res 2020;12:1741-1750.
  2. Afkham A, Aghebati-Maleki L, Siahmansouri H, Sadreddini S, Ahmadi M, Dolati S, Afkham NM, Akbarzadeh P, Jadidi-Niaragh F, Younesi V, Yousefi M. Chitosan (CMD)-mediated co-delivery of SN38 and Snail-specific siRNA as a useful anticancer approach against prostate cancer. Pharmacol Rep. 2018;70:418-425.
  3. Mullane SA, Van Allen EM. Precision medicine for advanced prostate cancer. Curr Opin Urol 2016;26:231-239.
  4. Parol M, Gzil A, Bodnar M, Grzanka D. Systematic review and meta-analysis of the prognostic significance of microRNAs related to metastatic and EMT process among prostate cancer patients. J Transl Med 2021;19:1-24.
  5. Fontana F, Raimondi M, Marzagalli M, Sommariva M, Limonta P, Gagliano N. Epithelial-to-mesenchymal transition markers and CD44 isoforms are differently expressed in 2D and 3D cell cultures of prostate cancer cells. Cells 2019;8:143.
  6. Yu H, Shen Y, Hong J, Xia Q, Zhou F, Liu X. The contribution of TGF-β in Epithelial–Mesenchymal Transition (EMT): Down-regulation of E-cadherin via snail. Neoplasma 2015;62:1-15.
  7. Banerjee S, Singh SK, Chowdhury I, Lillard Jr JW, Singh R. Combinatorial effect of curcumin with docetaxel modulates apoptotic and cell survival molecules in prostate cancer. Front Biosci (Elite Ed) 2017;9:235.
  8. Hoffman A, Sasaki H, Roberto D, Mayer MJ, Klotz LH, Venkateswaran V. Effect of Combination therapy of Desmopressin and Docetaxel on prostate cancer cell (DU145) proliferation, migration and tumor growth. J Cancer Biol Therap 2016;1:129-136.
  9. Park CH, Han SE, Nam-Goong IS, Kim YI, Kim ES. Combined effects of baicalein and docetaxel on apoptosis in 8505c anaplastic thyroid cancer cells via downregulation of the ERK and Akt/mTOR pathways. Endocrinol Metab 2018;33:121-132
  10. Lu X, Yang F, Chen D, Zhao Q, Chen D, Ping H, Xing N. Quercetin reverses docetaxel resistance in prostate cancer via androgen receptor and PI3K/Akt signaling pathways. Int J Biol Sci 2020;16:1121-1134.
  11. Lee LD, Mafura B, Lauscher JC, Seeliger H, Kreis ME, Gröne J. Antiproliferative and apoptotic effects of telmisartan in human colon cancer cells. Oncol Lett 2014;8:2681-2686.
  12. Funao K, Matsuyama M, Kawahito Y, Sano H, Chargui J, Touraine J-L, Nakatani T, Yoshimura R. Telmisartan as a peroxisome proliferator-activated receptor-γ ligand is a new target in the treatment of human renal cell carcinoma. Mol Med Rep 2009;2:193-198.
  13. Funao K, Matsuyama M, Kawahito Y, Sano H, Chargui J, Touraine JL, Nakatani T, Yoshimura R. Telmisartan is a potent target for prevention and treatment in human prostate cancer. Oncol Rep 2008;20:295-300.
  14. Kobara H, Fujihara S, Iwama H, Matsui T, Fujimori A, Chiyo T, Tingting S, Kobayashi N, Nishiyama N, Yachida T, Tadokoro T, Oura K, Tani J, Fujita K, Nomura T, Yoneyama H, Morishita A, Okano K, Suzuki Y, Mori H, Masaki T. Antihypertensive drug telmisartan inhibits cell proliferation of gastrointestinal stromal tumor cells in vitro. Mol Med Rep 2020;22:1063-1071.
  15. Abbasi A, Mostafavi-Pour Z, Amiri A, Keshavarzi F, Nejabat N, Ramezani F, Sardarian A, Zal F. Chemoprevention of Prostate Cancer Cells by Vitamin C plus Quercetin: role of Nrf2 in Inducing Oxidative Stress. Nutr Cancer 2020:1-11.
  16. Wu GS, Lu JJ, Guo JJ, Huang MQ, Gan L, Chen XP, Wang YT. Synergistic anti-cancer activity of the combination of dihydroartemisinin and doxorubicin in breast cancer cells. Pharmacol Rep 2013;65:453-459.
  17. Pfaffl MW. A new mathematical model for relative quantification in real-time RT–PCR. Nucleic Acids Res 2001;29:e45.
  18. Chou TC. Theoretical basis, experimental design, and computerized simulation of synergism and antagonism in drug combination studies. Pharmacol Rev 2006;58:621-681.
  19. Elwakeel A, Soudan H, Eldoksh A, Shalaby M, Eldemellawy M, Ghareeb D, Abouseif M, Fayad A, Hassan M, Saeed H. Implementation of the Chou-Talalay method for studying the in vitro pharmacodynamic interactions of binary and ternary drug combinations on MDA-MB-231 triple negative breast cancer cells. Synergy 2019;8:100047.
  20. Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer statistics, 2021. CA Cancer J Clin 2021;71:7-33.
  21. Mansour M, van Ginkel S, Dennis JC, Mason B, Elhussin I, Abbott K, Pondugula SR, Samuel T, Morrison E. The combination of omega-3 stearidonic acid and docetaxel enhances cell death over docetaxel alone in human prostate cancer cells. J Cancer 2018;9:4536-4546.
  22. Inamura S, Ito H, Taga M, Tsuchiyama K, Hoshino H, Kobayashi M, Yokoyama O. Low-dose Docetaxel Enhanced the Anticancer Effect of Temsirolimus by Overcoming Autophagy in Prostate Cancer Cells. Anticancer Res 2019;39:5417-5425.
  23. Matsuyama M, Funao K, Kuratsukuri K, Tanaka T, Kawahito Y, Sano H, Chargui J, Touraine J-L, Yoshimura N, Yoshimura R. Telmisartan inhibits human urological cancer cell growth through early apoptosis. Exp Ther Med 2010;1:301-306.
  24. Koyama N, Nishida Y, Ishii T, Yoshida T, Furukawa Y, Narahara H. Telmisartan induces growth inhibition, DNA double-strand breaks and apoptosis in human endometrial cancer cells. PLoS One. 2014;9:e93050.
  25. Uemura H, Hasumi H, Kawahara T, Sugiura S, Miyoshi Y, Nakaigawa N, Teranishi Ji, Noguchi K, Ishiguro H, Kubota Y. Pilot study of angiotensin II receptor blocker in advanced hormone-refractory prostate cancer. Int J Clin Oncol 2005;10:405-410.
  26. Matsui T, Chiyo T, Kobara H, Fujihara S, Fujita K, Namima D, Nakahara M, Kobayashi N, Nishiyama N, Yachida T, Morishita A, Iwama H, Masaki T. Telmisartan Inhibits Cell Proliferation and Tumor Growth of Esophageal Squamous Cell Carcinoma by Inducing S-Phase Arrest In Vitro and In Vivo. Int J Mol Sci. 2019;20:3197.
  27. Fujita N, Fujita K, Iwama H, Kobara H, Fujihara S, Chiyo T, Namima D, Yamana H, Kono T, Takuma K, Hirata M, Kobayashi K, Kato K, Kamada H, Morishita A, Tsutsui K, Himoto T, Okano K, Suzuki Y, Masaki T. Antihypertensive drug telmisartan suppresses the proliferation of gastric cancer cells in vitro and in vivo. Oncol Rep 2020;44:339-348.
  28. Green R, Howell M, Khalil R, Nair R, Yan J, Foran E, Katiri S, Banerjee J, Singh M, Bharadwaj S, Mohapatra SS, Mohapatra S. Actinomycin D and telmisartan combination targets Lung cancer Stem cells through the Wnt/Beta catenin pathway. Sci Rep 2019;9:1-13.
  29. Zhang S, Wang Y. Telmisartan inhibits NSCLC A549 cell proliferation and migration by regulating the PI3K/AKT signaling pathway. Oncol Lett 2018;15:5859-5864.
  30. Tian H, Yang J, Xie Z, Liu J. Gliquidone alleviates diabetic nephropathy by inhibiting notch/snail signaling pathway. Cell Physiol Biochem 2018;51:2085-2097.
  31. Liu Y, Chen S, Liu J, Jin Y, Yu S, An R. Telmisartan inhibits oxalate and calcium oxalate crystal-induced epithelial-mesenchymal transformation via PPAR-γ-AKT/STAT3/p38 MAPK-Snail pathway. Life Sci 2020;241:117108.
  32. Baygi ME, Soheili ZS, Essmann F, Deezagi A, Engers R, Goering W, Schulz WA. Slug/SNAI2 regulates cell proliferation and invasiveness of metastatic prostate cancer cell lines. Tumor Biol 2010;31:297-307.

Files

Share

How to cite

Statistics